source
- Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOsParkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug developers to eye up a public listing.Fierce Biotech · 10d ago↗ source
- Hengrui secures $15.2 billion Bristol Myers deal and pivots to co-development with Western partnersHengrui Pharmaceuticals has become a leading source of innovative drugs in China, outpacing many peers in the current licensing boom. In May the company signed a $15.2 billion licensing pact with…